Sugi Predict

Sugi Predict / Compounds / SCHEMBL642704

SCHEMBL642704

SCHEMBL642704

CC(Br)c1cccc2cccnc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PSMD14 O00487 1/20 0.52
▸ COPS5 Q92905 1/20 0.52
▸ MAPT P10636 3/20 0.50
▸ LMNA P02545 3/20 0.50
▸ KDM4E B2RXH2 3/20 0.50
▸ CCR1 P32246 3/20 0.50
▸ CCR5 P51681 3/20 0.50
▸ CCR8 P51685 3/20 0.50
▸ MMP2 P08253 2/20 0.50
▸ TSHR P16473 2/20 0.50
▸ TP53 P04637 2/20 0.50
▸ ALOX15 P16050 2/20 0.50
▸ HTT P42858 2/20 0.50
▸ TDP1 Q9NUW8 2/20 0.50
▸ GMNN O75496 1/20 0.50
▸ HSP90AA1 P07900 1/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ CYP2D6 P10635 1/20 0.50
▸ MMP9 P14780 1/20 0.50
▸ NFKB1 P19838 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL84502 0.84 PSMD14 (0.55) PSMD14COPS5MAPTLMNAKDM4E
SCHEMBL31490195 0.84 PSMD14 (0.55) PSMD14COPS5MAPTLMNAKDM4E
SCHEMBL3926154 0.81 PSMD14 (0.52) PSMD14COPS5MAPTLMNAKDM4E
SCHEMBL17541529 0.81 MMP2 (0.52) PSMD14COPS5MAPTLMNAKDM4E
SCHEMBL31230598 0.81 PSMD14 (0.52) PSMD14COPS5MAPTLMNAKDM4E
SCHEMBL14146709 0.81 PSMD14 (0.52) PSMD14COPS5MAPTLMNAKDM4E
SCHEMBL3707454 0.81 PSMD14 (0.52) PSMD14COPS5MAPTLMNAKDM4E
SCHEMBL17541536 0.81 PSMD14 (0.52) PSMD14COPS5MAPTLMNAKDM4E
SCHEMBL21369324 0.81 PSMD14 (0.52) PSMD14COPS5MAPTLMNAKDM4E
SCHEMBL29783529 0.81 PSMD14 (0.52) PSMD14COPS5MAPTLMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11332459-B2 Benzimidazole derivatives and their uses TEIJIN PHARMA LIMITED (JP) 2022-05-17 — — US disclosed
US-10889555-B2 Sulfonamide compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-01-12 — — US disclosed
US-20200405697-A1 Antitumor Agent TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-12-31 — — US disclosed
US-20200399235-A1 Sulfonamide Compound or Salt Thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-12-24 — — US disclosed
EP-3718545-A1 ANTITUMOR AGENT Taiho Pharmaceutical Co., Ltd. (JP) 2020-10-07 — — EP disclosed
US-20200308145-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USES AMGEN INC. (US) 2020-10-01 — — US disclosed
US-20200157066-A1 Sulfonamide Compound or Salt Thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-05-21 — — US disclosed
EP-3466934-A1 SULFONAMIDE COMPOUND OR SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2019-04-10 — — EP disclosed
WO-2017209155-A1 SULFONAMIDE COMPOUND OR SALT THEREOF 大鵬薬品工業株式会社 2017-12-07 — — WO disclosed
CN-104379573-A Isoindolone derivatives ABBVIE INC 2015-02-25 — — CN disclosed
US-20100076020-A1 QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS ALLERGAN, INC. (US) 2010-03-25 — — US disclosed
US-20100076020-A1 QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS ALLERGAN, INC. (US) 2010-03-25 — — US disclosed
WO-2009140138-A1 QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS ALLERGAN, INC. (US) 2009-11-19 — — WO disclosed
WO-2009140138-A1 QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS ALLERGAN, INC. (US) 2009-11-19 — — WO disclosed
US-20090286829-A1 QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS ALLERGAN, INC. (US) 2009-11-19 — — US disclosed
US-20090286829-A1 QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS ALLERGAN, INC. (US) 2009-11-19 — — US disclosed
US-20090286829-A1 QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS ALLERGAN, INC. (US) 2009-11-19 — — US disclosed
CN-101535303-A Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level NOVARTIS AG (CH) 2009-09-16 — — CN disclosed
WO-2008088937-A1 QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS ALLERGAN, INC. (US) 2008-07-24 — — WO disclosed
CN-101151246-A 1-benzylindole-2-carboxamide derivatives ORGANON NV (NL) 2008-03-26 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200399235-A1 Sulfonamide Compound or Salt Thereof RNASEH1, SNRPA1, RRM2 PSMD14 2571/4885COPS5 1435/4885MAPT 4312/4885
US-20100076020-A1 QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS TUBB3, TUBB1, NQO2 PSMD14 3891/4885COPS5 724/4885MAPT 2162/4885
US-20090286829-A1 QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS ADRA2C, ADRA2B, ADRB3 PSMD14 3048/4885COPS5 1384/4885MAPT 2033/4885
US-20200308145-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USES TRPC6, TRPV6, TRPM6 PSMD14 4355/4885COPS5 4011/4885MAPT 3674/4885
US-20200157066-A1 Sulfonamide Compound or Salt Thereof RNASEH1, SNRPA1, RRM2 PSMD14 2571/4885COPS5 1435/4885MAPT 4312/4885
US-10889555-B2 Sulfonamide compound or salt thereof RNASEH1, SNRPA1, RRM2 PSMD14 2571/4885COPS5 1435/4885MAPT 4312/4885
US-11332459-B2 Benzimidazole derivatives and their uses TRPC6, TRPV6, TRPM6 PSMD14 4355/4885COPS5 4011/4885MAPT 3674/4885
US-20200405697-A1 Antitumor Agent HNRNPR, RRM2, RRM2B PSMD14 2047/4885COPS5 2307/4885MAPT 4815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.